SR9009 — Background and Chemical Identity

• Chemical name / synonyms: SR9009; Stenabolic. Wikipedia+2Tocris Bioscience+2
• CAS number: 1379686‑30‑2 Wikipedia+1
• Mechanism of action: SR9009 is a synthetic small‑molecule agonist of nuclear receptors REV-ERBα and REV-ERBβ. By binding these receptors, SR9009 increases their repressor activity — influencing circadian rhythm regulation, metabolism, and gene expression tied to energy homeostasis. Wikipedia+2DrugBank+2
• Experimental status: SR9009 is classified as an “experimental” / “research” compound. There is no regulatory approval for therapeutic or lifestyle use. DrugBank+1

Research Evidence: Effects, Metabolism, and Biological Activity

• Animal studies demonstrated that SR9009 increased exercise endurance and improved metabolic performance. SciTechDaily+2Wikipedia+2
• In a chronic animal‑model study with disturbed circadian rhythm and metabolic disruption (constant light exposure), low-dose SR9009 (10 mg/kg daily) reduced weight gain, decreased white fat mass, and improved insulin resistance. PubMed+1
• In vitro and cell studies suggest SR9009 can rewire cellular metabolism, influence gene transcription, and even exert cytotoxic effects in certain cancer cell lines — though these effects may not depend solely on REV-ERB activation. PMC+2PubMed+2
• SR9009 has been shown to suppress inflammatory responses: for example, in mouse macrophages, SR9009 inhibited LPS-induced inflammatory signaling — linked to changes in gene expression via REV-ERBα. ScienceDirect
• Metabolic studies for compound detection and metabolism have identified multiple SR9009 metabolites via high-resolution mass spectrometry — relevant for analytical / doping-control contexts. Analytical Science Journals+1

Proposed/Potential Benefits (Based on Preclinical Data)

• Increased exercise endurance & capacity — In animal studies, SR9009 administration was associated with enhanced endurance and improved metabolic efficiency, suggesting it may mimic some effects of exercise. SciTechDaily+2Wikipedia+2
• Metabolic modulation: fat loss, improved lipid/metabolic profile — Animal data show reductions in fat mass, lowered weight gain under metabolic stress, and improvements in insulin sensitivity. PubMed+2ScienceDirect+2
• Potential cardioprotective / tissue‑protective effects (in some contexts) — In a heart stress model (pressure overload), SR9009 ameliorated adverse heart remodeling — though mechanisms may be independent of REV‑ERB receptors. PMC
• Anti-inflammatory effects — In cellular models, SR9009 suppressed inflammatory signaling (e.g. via inhibiting NLRP3 transcription in macrophages), indicating possible immunomodulatory potential. ScienceDirect
• Modulation of circadian rhythm & metabolic regulation — Because REV-ERB receptors are part of the molecular circadian clock, SR9009’s action may influence energy homeostasis, metabolism, and circadian regulation — which could have wide-ranging biological implications (metabolic disease, diabetes, obesity, etc.). Wikipedia+2ChemicalBook+2

Known Risks, Limitations, and Key Concerns

• Lack of human clinical data: The majority of evidence comes from animal models, in vitro assays, or cell studies. There is little to no publicly available well-controlled human trial data on safety, efficacy, dosing, or long-term effects.
• Uncertain specificity / off-target effects: Some research indicates that SR9009’s effects may not always depend exclusively on REV-ERB activation, meaning its actions might involve other, poorly characterized pathways — raising unpredictability. PMC+1
• Metabolism and detection complexity: SR9009 is metabolized into multiple derivatives; while this is useful for analytical detection, it also shows that the compound undergoes transformation — which could lead to unknown metabolites, unknown toxicity, or unintended actions. Analytical Science Journals+1
• Regulatory and legality issues; doping risk: SR9009 is on the prohibited list of World Anti-Doping Agency (WADA) — use in athletic contexts is disallowed. Wikipedia+1
• Research‑use only status: Suppliers of SR9009 typically label it strictly “for research use only — not for human consumption, medical, or veterinary use.” Cayman Chemical+1
• Unpredictable long-term effects / safety profile: Because no long-term studies exist — especially in humans — potential risks remain unknown: chronic toxicity, organ damage, metabolic dysregulation, undesired gene expression changes, etc.

Why “Injectable SR9009” Is Particularly Problematic / Unsupported

• All formal studies of SR9009 — animal or in vitro — use non-injectable administration (often oral dosing, or controlled laboratory delivery). There is no peer-reviewed evidence documenting safety, pharmacokinetics, or efficacy for an “injectable” formulation.
• Any injectable variant would likely come from unregulated or black-market sources — which poses high risk of contamination, dosing errors, unknown sterility, unknown formulation stability, or unexpected impurities.
• Suppliers themselves often state SR9009 is “for research only” and not for human or therapeutic use. Kimera Chems+1
• Use outside controlled research (especially in an injectable form) would represent unapproved, off-label experimentation — with unpredictable and potentially serious health consequences.

Summary / Conclusion (As of Current Research)

SR9009 is a potent synthetic agonist of REV-ERB nuclear receptors, with preclinical data (animal and cell studies) showing promising effects: enhanced metabolic performance, fat loss, improved exercise endurance, possible cardioprotective & anti-inflammatory effects, and modulation of metabolic/circadian regulation. However, there is no robust human clinical data. The compound remains an “experimental” research chemical — and any non‑clinical use (especially injectable) is unapproved, unsafe, and carries unknown risks.

From a scientific perspective, SR9009 may warrant further investigation (in controlled preclinical or clinical trials) for metabolic, inflammatory, or cardiovascular applications. But from a safety / public-health perspective: its use outside of controlled research is highly risky, ethically and medically unsubstantiated.

For these reasons, any consideration of SR9009 must be strictly within regulated scientific research contexts.

Frequently Asked Questions (FAQ) about SR9009

1. What is SR9009 and what is its CAS number?
   • SR9009 (Stenabolic) is a synthetic agonist of REV-ERBα/β receptors. Its CAS number is 1379686‑30‑2. Wikipedia+1
2. Is SR9009 approved for medical use in humans?
   • No. It is classified as an experimental research compound. There is no regulatory approval for therapeutic, lifestyle, or bodybuilding use. DrugBank+1
3. What benefits have researchers observed with SR9009 (in studies)?
   • In animal studies: improved exercise endurance, increased metabolic activity, reduced fat mass, better insulin sensitivity under metabolic stress, and potential cardioprotective and anti‑inflammatory effects. PMC+3SciTechDaily+3PubMed+3
4. Has SR9009 been tested in humans?
   • To date, there is no publicly available published study demonstrating safety or efficacy of SR9009 in humans.
5. What are the main risks or unknowns with SR9009?
   • Because human data is lacking, long-term safety, toxicity, dosing parameters, organ effects, metabolic consequences, and off-target effects are unknown. Also, the compound may act via unknown or multiple mechanisms, adding unpredictability.
6. Are there known side effects or harmful outcomes in preclinical research?
   • Some in vitro studies show cytotoxicity (e.g., decreased cell viability, altered cell cycle) in cancer cell lines and hepatocytes under SR9009 exposure. PubMed+1
   • But these are cell-line specific experiments; they do not directly translate to safety or side-effect profiling in living humans.
7. Can SR9009 be used as an “exercise substitute” or fat‑loss aid safely?
   • No safe, well‑studied protocol exists for that. Animal data are preliminary; human effects, safety, optimal dosing, and long-term consequences are entirely unknown.
8. What about “injectable SR9009” — is that validated by research?
   • No. There is no peer-reviewed evidence for injectable SR9009. All published research uses non-injectable administration. Any injectable form would likely be unregulated, with unknown purity, dosing, sterility — and represents high-risk off-label use.
9. Is SR9009 banned or regulated in sports?
   • Yes. SR9009 is considered a prohibited metabolic modulator / performance‑enhancing agent under doping rules (e.g., WADA). Wikipedia+1
10. Given what is known — is SR9009 a good candidate for further research or development?
    • Yes — from a scientific research perspective. The preclinical data suggest interesting potential for metabolic modulation, inflammation, circadian rhythm regulation, and possibly cardiovascular protection. However — for any therapeutic use — rigorous, controlled, and ethically approved studies would be required (pharmacokinetics, toxicology, dose-finding, long-term effects).

Important Disclaimer

This document is provided for research and educational purposes only. SR9009 is not approved for medical, veterinary, performance‑enhancing, or dietary use. The safety, efficacy, and long-term effects of SR9009 (especially in humans, or in injectable form) remain unproven. Use of SR9009 outside of controlled, ethically‑approved research settings carries significant risk and unpredictability.